Michael D. Feldman
Sign in to view more
CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome prediction.
Abstract P2-08-03: Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
Computer extracted features of gland morphology on H&E surgically resected tissue images as predictive of biochemical recurrence and rate of expression in African American compared to Caucasian American men.